Table 3 Hazard ratio (HR) value for the NSCLC subgroup according to histology, stage and laboratory technique

From: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  

Nb

Patients

Fixed effects HR (95% CI)

χ 2 Heterogeneity test

Random effects HR (95% CI)

Overall

 

28

3620

1.30 (1.20–1.49)

P=0.01

1.35 (1.16–1.56)

Histology

Squamous

4

280

1.49 (0.88–2.52)

P=0.48

 
 

ADC

15

1436

1.52 (1.30–1.78)

P=0.02

1.59 (1.26–2.02)

Disease stage

Stages I

5

562

1.26 (0.94–1.69)

P=0.43

 
 

Stages I–III

7

882

1.20 (0.93–1.53)

P=0.42

 
 

Stages I–IV

11

1553

1.25 (1.04–1.50)

P<0.001

1.41 (0.99–1.99)

Laboratory method

IHC

7

989

1.08 (0.86–1.34)

P=0.21

 
 

PCR

23

2631

1.39 (1.22–1.58)

P=0.03

1.40 (1.18–1.65)

PCR subgroups

RFLP

6

765

1.70 (1.31–2.19)

P=0.53

 
 

SSCP

3

361

1.32 (0.72–1.47)

P=0.06

 

ADC

IHC

4

266

1.57 (1.13–2.16)

P=0.01

1.48 (0.76–2.87)

 

PCR

11

1170

1.50 (1.26–1.80)

P=0.1

 
  1. Nb=number of studies; ADC=adenocarcinomas; IHC=immunohistochemistry; PCR=polymerase chain reaction; SSCP=single-strand conformation polymorphism; RFLP=restriction fragment length polymorphism; statistically significant results are in bold.
Back to article page